Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

Paused

Conditions studied: Bladder Cancer

In brief

The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.

Key facts

Study ID

NCT05643690

Run by

AnchorDx Medical Co. Ltd. US

People needed

77

Starts

2022-11-18

Expected to finish

2025-12-31

Last updated by the study team

2024-06-06

Who can join

Age: 55 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical Validation Group:
• 55 years or older, gender is not limited
• Suspected of bladder cancer and are scheduled for bladder biopsy or trans-uretheral resection of bladder tumor (TUBRT)
• Can receive standard of care, including urine cytology, cystoscopy, or surgery for bladder cancer diagnosis
• Can provide at least of 75 ml of urine (prior to cystoscopy or surgery)

You may not qualify if…

• History of urinary cancer
• Neoadjuvant therapy

Where it is running

• Arkansas Urology — Little Rock, Arkansas, United States
• Idaho Urologic Institute — Meridian, Idaho, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.